Centro de Salud La Algaba
La Algaba, Sevilla, 41980, Spain
NCT Number: NCT04935957
This study is a prospective, single center, non-interventional, open label clinical investigation. The primary objective of the study is to evaluate the performance of GLUCUBE system compared to the standard glucometer in the determination of blood glucose level in adult patients.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
La Algaba, Sevilla, 41980, Spain
The current methods for blood glucose measurements, glucometers, although minimally invasive, can be painful, requiring puncturing the fingertip with a lancet device and removing a drop of blood, that applies to a disposable test strip. This minimal invasiveness may cause discomfort and deter the user from measuring his/her blood glucose levels as frequently as required. Due to GLUCUBE device non-invasive nature, it is expected to give the patient or health care provider immediate reliable quantitative as well as qualitative information, safely and painlessly avoiding any type of discomfort to the user.
This study is a prospective, single center, non-interventional, open label clinical investigation designed with a total amount of 105 subjects. Study participants will take the GLUCUBE device and standard glucometer home and each subject will take 4 pairs of measurements per day for a week.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
device to monitor and measure the blood glucose compared to the standard glucometer in a group subjects
Other names: GLUCUBE
Time frame: 4 times/day for 1 week
GLUCUBE system performance in the monitoring and measurement of the blood glucose compared to the standard glucometer (blood capillary glucometer - Bayer Contour®Next).
Each pair of measurements includes one measurement with the standard glucometer (Bayer Contour®Next) and one measurement with GLUCUBE device.
Time frame: All AE will be collected during participation in the study since V1 at V2 (8 days)
All (Serious) Adverse Events and GLUCUBE device related adverse events: local and systemic effects of GLUCUBE device, and the standard glucometer, including, but not limited to redness, burns, pain, or other complications such as bleeding or local infection will be collected.
Time frame: through study completion, an average of 8 days
GLUCUBE system performance in the monitoring and measurement of the blood glucose compared to the standardized POC device for the determination of glucose (Accu-Chek® Inform II system).
Each pair of measurements includes one measurement with standardized POC device for the determination of glucose (Accu-Chek® Inform II system) and one measurement with GLUCUBE device.
Time frame: 8 days after the participant enters the study
Patient reported satisfaction related to the investigational device: in a 1 to 10 scale: 1 - Disagree, 10 - Agree.
And, if given the choice, will you use GLUCUBE device again? Yes or No
iGluco
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07043478
Blood Glucose, Healthy
London, Ontario, Canada
View Trial DetailsNCT07187648
Blood Glucose, Blood-Borne Infections
Makassar, South Sulawesi, Indonesia
View Trial DetailsNCT06497972
Blood Glucose
Winnipeg, Manitoba, Canada
View Trial DetailsNCT06458946
Blood Glucose, Blood Insulin
Addison, Illinois, United States
View Trial Details